DIRS.INFO The most relevant business & tech news

☆ Stocks making the biggest premarket moves: Boeing, Dell, Merck and more
▼ + stars: | 2024-09-09 | by ( Michelle Fox | ) www.cnbc.com time to read: +2 min

MarineMax — Shares jumped 6% after Citi upgraded shares to buy from neutral. Palantir Technologies , Dell Technologies — Shares of Palantir and Dell rallied 8% and 5%, respectively, after it was announced postmarket Friday that the stocks would join the S & P 500 index. Palantir will replace American Airlines , while Dell will replace Etsy . Summit shares soared more than 30%. United States Steel — Shares moved about 3% higher after JPMorgan upgraded the industrial stock to overweight from neutral.

Persons: Merck, Summit, —, Jesse Pound, Hakyung Kim, Sarah Min, Sean Conlon Organizations: Boeing —, Citi, Technologies, Dell Technologies, Dell, American Airlines, Etsy, Summit Therapeutics, Summit, Arm Holdings, Times, Apple, United States Steel, JPMorgan, Nippon Steel, JetBlue Airways —, Bank of America, JetBlue

☆ Stocks making the biggest moves midday: Palantir Technologies, Summit Therapeutics, JetBlue Airways and more
▼ + stars: | 2024-09-09 | by ( Sean Conlon | ) www.cnbc.com time to read: +2 min

Check out the companies making headlines in midday trading: Palantir Technologies , Dell Technologies — Palantir and Dell jumped 14% and nearly 4%, respectively, following the announcement after the bell Friday that both stocks would join the S & P 500 before the open on Sept. 23. Palantir is set to take American Airlines' spot, while Dell is going to replace Etsy. JetBlue Airways — The airline stock popped around 7% after Bank of America analyst Andrew Didora upgraded the firm to neutral from underperform. Cannabis stocks — Cannabis stocks moved higher after former President Donald Trump said in a Truth Social post that he will support legalizing adult marijuana use in Florida. A logo outside the Palantir Technologies pavilion ahead of the World Economic Forum in Davos, Switzerland, on Jan. 15, 2024.

Persons: Dell, Merck's, Andrew Didora, Didora, Arm's, Donald Trump, —, Alex Harring, Hakyung Kim, Yun Li, Jesse Pound, Michelle Fox, Stefan Wermuth Organizations: Palantir Technologies, Dell Technologies, American Airlines, Etsy, Therapeutics, Merck, JetBlue Airways —, Bank of America, JetBlue, Boeing, Citi, Federal Reserve, Arm Holdings, Financial, Apple, Monday, United States Steel, JPMorgan, Nippon Steel, Tilray Brands, Cannabis ETF, Economic, Bloomberg, Getty Locations: Florida, Davos, Switzerland

☆ Stocks making the biggest moves premarket: United States Steel, Unity Software, Boeing and more
▼ + stars: | 2024-09-03 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +2 min

United States Steel — The industrial stock plunged 6% after Vice President Kamala Harris opposed the planned sale of United States Steel to Japan's Nippon Steel. She made these statements during a Labor Day rally in front of union members in Pittsburgh, Pennsylvania, where she said that United States Steel was "an historic American company and it is vital for our country to maintain strong American steel companies." NetApp — The data storage stock added 1.6% following an upgrade to buy from hold at Loop Capital. Loop analyst Ananda Baruah listed several catalysts, including NetApp's cloud storage software partnerships and a recent pullback. Bank of America — The bank stock was down fractionally.

Persons: Kamala Harris, Wells, Matthew Akers, Morgan Stanley, Ananda Baruah, Jefferies, Peter Welford, Warren Buffett's Berkshire, Merck's Keytruda, — CNBC's Michelle Fox, Jesse Pound Organizations: United States Steel, Japan's Nippon Steel, Labor, Boeing, Software, Novartis —, Novartis, Bank of America, Warren Buffett's Berkshire Hathaway, Merck, European Commission Locations: Pittsburgh , Pennsylvania, American, Warren

☆ Moderna, Merck say vaccine improved survival in patients with deadly skin cancer
▼ + stars: | 2024-06-03 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

Moderna and Merck released more positive three-year data Monday on their experimental vaccine, given to patients with the most deadly form of skin cancer in combination with the therapy Keytruda. The vaccine together with Merck's Keytruda improved survival and showed long-lasting efficacy in a midstage study in patients with a deadly form of skin cancer. Melanoma is responsible for the large majority of skin cancer deaths, according to the American Cancer Society. Moderna is also conducting another phase three trial of the vaccine in patients with a type of lung cancer. This year, Merck and Moderna started a two-part mid- to late-stage trial on the vaccine and Keytruda in patients at an advanced stage of a common skin cancer.

Persons: Merck's, Kyle Holen, Keytruda, Stephane Bancel, Bancel Organizations: Moderna, Merck, American Society of Clinical Oncology, CNBC, U.S . Food, Drug Administration, FDA, American Cancer Society Locations: Chicago, U.S, Moderna

Three names in the industry – Johnson & Johnson , Merck and Bristol Myers Squibb – face a pivotal few weeks ahead. They join Bristol Myers Squibb CEO Chris Boerner, who agreed to the panel's initial invitation to appear. But why is the committee targeting Merck, J&J and Bristol Myers Squibb in the first place? J&J, Merck and Bristol Myers Squib are all suing to halt the talks, which will establish new prices that will go into effect in 2026. Bristol Myers Squibb's Opdivo is an immunotherapy used to treat cancers, including melanoma and lung cancer.

Persons: Annika Kim Constantino, – Johnson, Sen, Bernie Sanders, Joaquin Duato, Robert Davis, Chris Boerner, Sanders, Eli Lilly's, Januvia, Bristol Myers, He's, Biden, Merck's, Myers, Eliquis, Mike Perrone, it's Organizations: CNBC.com, Johnson, Merck, Bristol Myers Squibb, Bristol Myers, Medicare, Bristol, CNBC, pharma Locations: U.S, drugmakers

☆ Big pharma is at a crossroads, as J&J, Merck and others prepare to lose heaps of revenue from blockbuster drugs
▼ + stars: | 2024-01-28 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +12 min

Bristol Myers Squibb's Eliquis is a blood thinner used to prevent clotting, to reduce the risk of stroke. Bristol Myers Squibb's Opdivo is an immunotherapy used to treat cancers, including melanoma and lung cancer. Investors will get updates on Merck and Bristol Myers Squibb's plans for the years ahead when they report earnings on Thursday and Friday, respectively. That's unlike generics, which are cheaper copycats of small-molecule drugs like Bristol Myers Squibb's Eliquis. Bristol Myers Squibb is also testing a new form of Opdivo, which is currently administered into a patient's veins.

Persons: Johnson, William Blair, Matt Phipps, Bristol Myers, Johnson's, Merck's Keytruda, J's Stelara, Opdivo, Phipps, biosimilars, Eliquis, Biosimilars, Humira, JB Reed, Samsung's, Piper Sandler, Christopher Raymond, AbbVie, Raymond, Chris Schott, Schott, Robert Davis, Keytruda, Davis, JPMorgan's Schott, Bristol Myers Squibb, George Frey, J, Amgen, J confidentially, Mike Perrone, It's, Anna Moneymaker Organizations: New York Stock Exchange, Johnson, NYSE Big, Bristol Myers Squibb, Merck, Biden, William Blair & Company, CNBC, Guggenheim, Bristol, Leerink Partners, Bloomberg, Getty, Bioepis, JPMorgan, JPMorgan Health Care, Moderna, Bristol Myers, Karuna Therapeutics, Hardy, Huntsman Cancer Institute, University of Utah, Reuters, Teva Pharmaceuticals, Pharma, U.S . Department of Health, Human Services Locations: drugmakers, EY, Europe, U.S, Cambridge , Massachusetts, Arda, EY's Americas, Bristol, Salt Lake City , Utah, Washington , DC

☆ Merck's Keytruda meets main goal in late-stage breast cancer study
▼ + stars: | 2023-07-28 | by ( ) www.reuters.com time to read: +1 min

July 28 (Reuters) - Merck (MRK.N) said on Friday its blockbuster drug Keytruda, in combination with chemotherapy, met one of the main goals in a late-stage trial testing it in some breast cancer patients. The study showed that the therapy was able to help clear all signs of tumor in patients compared to neo-adjuvant placebo plus chemotherapy. Breast cancer is one of the leading causes of cancer-related deaths in women. The therapy addresses the patients who are diagnosed with a sub-type of breast cancer, which has an increased risk of spread to lymph nodes and recurrence. Reporting by Khushi Mandowara in Bengaluru; Editing by Shilpi MajumdarOur Standards: The Thomson Reuters Trust Principles.

Persons: Khushi, Shilpi Majumdar Organizations: Merck, Thomson Locations: Bengaluru

☆ Cancer vaccines poised to unlock 'new treatment paradigm' with Merck/Moderna data
▼ + stars: | 2023-06-05 | by ( Julie Steenhuysen | ) www.reuters.com time to read: +5 min

The hope is for "a completely new treatment paradigm in cancer that will be better tolerated and unique to individual patients' tumors," said Dr. Jane Healy, an executive overseeing in early cancer treatment development at Merck. The Merck/Moderna collaboration is one of several combining powerful drugs that unleash the immune system to target cancers with mRNA vaccine technology. Aiming at these unique proteins allows the immune system to kill cancer cells while leaving healthy tissue unscathed. With standard treatment, 90% of pancreatic cancer patients die within five years of diagnosis. The approach first primes the immune system with an older technology called a chimpanzee adenovirus vaccine that targets patients' tumors.

Persons: Andrew Kelly, Keytruda, Jane Healy, Germany's BioNTech, Vinod Balachandran, we've, we're, Andrew Allen, Healy, Julie Steenhuysen, Caroline Humer, Bill Berkrot Organizations: Merck & Co, REUTERS, CHICAGO, Moderna Inc, American Society of Clinical Oncology, Merck, Moderna, Memorial Sloan Kettering Cancer Center, Thomson Locations: Kenilworth , New Jersey, U.S, Chicago, New York, Nature

☆ ASCO conference will put the focus on the fight against cancer. These stocks are in the spotlight
▼ + stars: | 2023-05-28 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +9 min

Developments in cancer research will be in the spotlight as the American Society of Clinical Oncology hosts the world's biggest cancer research conference in Chicago, starting Thursday. The pair has already has won regulatory approval for Enhertu for metastatic HER2-low breast cancer, but the companies are also studying its use in a variety other HER2 tumors in breast cancers. Lilly's drug, Verzenio, is used in high-risk patients with HR-positive HER2-negative breast cancer that is more likely to reoccur and has already breached the patient's lymph nodes. In a research note earlier this month, Guggenheim analyst Seamus Fernandez said Kisqali is already taking market share from Pfizer's Ibrance in metastatic breast cancer. Merck's Keytruda is also being watched for what benefits it could offer early-stage lung cancer patients .

☆ Bristol Myers CEO Caforio steps down
▼ + stars: | 2023-04-26 | by ( ) www.reuters.com time to read: +1 min

[1/2] A sign stands outside a Bristol Myers Squibb facility in Cambridge, Massachusetts, U.S., May 20, 2021. REUTERS/Brian Snyder/File PhotoCompanies Bristol-Myers Squibb Co FollowApril 26 (Reuters) - Bristol Myers Squibb Co (BMY.N) said on Wednesday CEO Giovanni Caforio, who has been in the role since 2015, has decided to step down from his position. Outgoing CEO Giovanni will continue as executive chairman of the company's board. Bristol Myers is due to report first-quarter financial results on Thursday. Bristol Myers shares rose 0.39% to $68.29 in after-hours trading.

The Merck/Moderna collaboration is one of several combining powerful drugs that unleash the immune system to target cancers with mRNA vaccine technology. BioNTech SE (22UAy.DE) and Gritstone Bio Inc (GRTS.O) are working on competing cancer vaccines based on mRNA technology. Barr said it took about eight weeks to design a personalized mRNA vaccine for each patient. In the past, similar experimental cancer vaccines were developed targeting a single tumor mutation, or neoantigen. With mRNA technology in combination with Keytruda, "we can create this shotgun approach ... that can create a more potent immune response," Barr said.

The Merck/Moderna collaboration is one of several combining powerful drugs that unleash the immune system to target cancers with mRNA vaccine technology. BioNTech SE (22UAy.DE) and Gritstone Bio Inc (GRTS.O) are working on competing cancer vaccines based on mRNA technology. Barr said it took Moderna about eight weeks to design a personalized mRNA vaccine for each patient. In the past, similar experimental cancer vaccines were developed targeting a single tumor mutation, or neoantigen. With mRNA technology in combination with Keytruda, "we can create this shotgun approach ... that can create a more potent immune response," Barr said.

☆ Senator Warren urges U.S. patent office to scrutinize Merck's Keytruda
▼ + stars: | 2023-02-23 | by ( Michael Erman | ) www.reuters.com time to read: +2 min

Senator Bernie Sanders, as well as Representatives Katie Porter and Pramila Jayapal also signed the letter. They expressed particular concern over Merck's efforts to patent a subcutaneous version of the currently infused drug, which Reuters reported on late last year. They wrote that Merck’s use of dozens of patents to fend off Keytruda competitors "appear(s) to be an example of the anti-competitive business practices ... that we have long beenconcerned about." Merck, which reported $20.9 billion in 2022 sales of Keytruda, has relied on the immunotherapy to fuel its growth. They urged Vidal to "give close scrutiny to any of Merck’s requests for new patents for Keytruda, and reject those that do not clearly meet the agency’s standards."

☆ This week's best performers include Moderna and two homebuilders
▼ + stars: | 2022-12-16 | by ( Samantha Subin | ) www.cnbc.com time to read: +2 min

As of Friday's open, these are some of the stocks poised to buck this week's negative trend. This week's top performer was vaccine maker Moderna , with shares up nearly 17% as of Friday's open. Homebuilding stocks Lennar and PulteGroup are also on pace to finish the week on a positive note. Shares of both stocks are down more than 19% this year, but were on pace to gain about 6% for the week as of Friday's open. About 47% of analysts say shares are a buy, offering 10.6% upside from Thursday's close.

☆ Moderna pops 17% after Merck exercises option to jointly develop a personalized cancer vaccine
▼ + stars: | 2022-10-12 | by ( Matthew Fox | ) www.businessinsider.com time to read: +3 min

Moderna spiked as much as 17% on Wednesday after the company teamed up with Merck to develop personalized cancer vaccines. Data from an ongoing phase 2 trial of Moderna's vaccine used in combination with Merck's Keytruda is expected in the fourth quarter. Under an existing licensing agreement that was initially inked in 2016, Merck had the option to exercise an option to jointly develop and sell the personalized cancer vaccines. Merck will pay Moderna $250 million to exercise its option, and will collaborate on the development and commercialization of the vaccines. Merck's cancer drug Keytruda is currently being evaluated in combination with Moderna's mRNA-4156/V940 vaccine as a treatment for patients with high-risk melanoma.

☆ Moderna and Merck will jointly develop a cancer vaccine for high-risk melanoma patients
▼ + stars: | 2022-10-12 | by ( Spencer Kimball | ) www.cnbc.com time to read: +2 min

Moderna this week started testingModerna and Merck will jointly develop and sell a cancer vaccine that is personalized for individual patients, the companies announced on Wednesday. Moderna's vaccine, based on its messenger RNA technology, is being studied in combination with Merck's Keytruda to treat patients with high-risk melanoma, the deadliest form of skin cancer, in a phase 2 trial. Moderna's vaccine is designed to trigger the immune system to deploy killer T cells that target the specific mutations of a patient's tumors. The companies originally entered the agreement in 2016, but Merck is now exercising its option through a $250 million payment to Moderna. Moderna expects $21 billion in Covid vaccine sales this year as it rolls out new booster shots that target the omicron variant.

☆ Stocks making the biggest moves midday: Moderna, Pepsi, Lyft and more
▼ + stars: | 2022-10-12 | by ( Michelle Fox | ) www.cnbc.com time to read: +3 min

Pepsi products are displayed for sale in a Target store on March 8, 2022 in Los Angeles, California. Check out the companies making the biggest moves midday Wednesday:Moderna — Shares of Moderna surged 10% after the drug maker announced it will partner with Merck to jointly develop and sell a cancer vaccine. It reported preliminary month-end assets under management of $1.23 trillion as of Sept. 30. Pepsi also raised its guidance for the year as it was able to successfully raise prices on its products. Lyft — Lyft shares gained 5.8% following an upgrade from Gordon Haskett to buy from hold.

☆ A series of mega-blockbuster drugs are on the horizon. How to invest in the trend
▼ + stars: | 2022-10-08 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +4 min

"That said, the biggest drugs usually feature one, or best case two, of these attributes." Seven drugs on Meacham's list are already in the market, and have already hit the $10 billion or more benchmark. That means some of these drugs may be already hitting the end of their peak sales period. Meacham has previously said that one of the drugs in this bucket, Eli Lilly's tirzepatide, could be the first $100 billion drug . But many investors are hopeful about its potential as an obesity treatment .

Search resuls for: "Merck's Keytruda"

18 mentions found